CVS Health Corporation (NYSE:CVS) Shares Purchased by TD Private Client Wealth LLC

TD Private Client Wealth LLC increased its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 152.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,914 shares of the pharmacy operator's stock after acquiring an additional 47,649 shares during the quarter. TD Private Client Wealth LLC's holdings in CVS Health were worth $5,346,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CVS. Dodge & Cox increased its stake in shares of CVS Health by 11.2% in the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares during the period. Capital World Investors increased its stake in shares of CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after purchasing an additional 12,819,148 shares during the period. Geode Capital Management LLC increased its stake in shares of CVS Health by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after purchasing an additional 689,867 shares during the period. Capital International Investors increased its stake in shares of CVS Health by 4.8% in the fourth quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after purchasing an additional 1,212,126 shares during the period. Finally, Pzena Investment Management LLC increased its stake in shares of CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Price Performance

CVS opened at $67.38 on Monday. The stock has a fifty day moving average of $65.11 and a 200-day moving average of $61.71. The firm has a market capitalization of $85.23 billion, a P/E ratio of 16.08, a PEG ratio of 0.97 and a beta of 0.57. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $72.51. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 earnings per share. Equities analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

Insider Activity

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The stock was bought at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director directly owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.22% of the stock is owned by insiders.

Analyst Ratings Changes

CVS has been the topic of several analyst reports. Wall Street Zen upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. UBS Group increased their price objective on shares of CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Royal Bank Of Canada increased their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Jefferies Financial Group increased their price objective on shares of CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a report on Monday, June 30th. Finally, Mizuho increased their price objective on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus target price of $75.06.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.